Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis SA is taking strategic steps to target a unique area within the growing obesity market. With therapies based on GLP-1 receptor agonists creating muscle loss concerns, Biophytis is focusing on solutions to preserve muscle mass and functionality. Their lead candidate, BIO101 (20-hydroxyecdysone), is pioneering the field as the first oral MAS receptor activator aimed at preventing GLP-1-induced muscle wastage.

Recent clinical trial successes involving similar muscle preservation agents underscore the necessity for such therapies. Biophytis sees this as an opportunity to capture a segment of the obesity market, projected to reach $100 billion by 2030. The company’s expertise in muscular diseases positions it to become a key player offering innovative solutions for muscle preservation.